Department of Surgery, Duke University Medical Center, Durham, North Carolina; Duke Clinical Research Institute, Durham, North Carolina.
Department of Surgery, SickKids, Toronto, Ontario, Canada.
JACC Cardiovasc Interv. 2020 Jul 13;13(13):1515-1525. doi: 10.1016/j.jcin.2020.04.029. Epub 2020 Jun 10.
This study sought to report the largest series of patients receiving a surgical reoperation after transcatheter aortic valve replacement (TAVR) using the Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database.
TAVR has become an effective means of treating aortic stenosis. As TAVR is used in progressively lower-risk cohorts, management of device failure will become increasingly important.
The STS Adult Cardiac Surgery Database was queried for patients with a history of prior TAVR undergoing surgical aortic valve replacement from 2011 to 2015. Observed-to-expected (O/E) mortality ratios were determined to facilitate comparison across reoperative indications and timing from index TAVR procedure.
A total of 123 patients met inclusion criteria (median age 77 years) with an STS Predicted Risk of Mortality of 4%, 4% to 8%, and >8% in 17%, 24%, and 59%, respectively. Median time to reoperation was 2.5 (interquartile range: 0.7 to 13.0) months, and the operative mortality rate was 17.1%. Common indications for reoperation included early TAVR device failures such as paravalvular leak (15%), structural prosthetic deterioration (11%), failed repair (11%), sizing or position issues (11%), and prosthetic valve endocarditis (10%). All pre-operative risk categories were associated with an increased O/E mortality ratio (Predicted Risk of Mortality <4%: O/E 5.5; 4% to 8%: O/E 1.7; >8%: O/E 1.2).
SAVR following early failure of TAVR, while rare, is associated with worse-than-expected outcomes as compared with similar patients initially undergoing SAVR. Continued experience with this developing technology is needed to reduce the incidence of early TAVR failure and further define optimal treatment of failed TAVR prostheses.
本研究旨在报告使用胸外科医师学会(STS)成人心脏外科学数据库接受经导管主动脉瓣置换术(TAVR)后再次接受外科手术的患者数量最多的系列病例。
TAVR 已成为治疗主动脉瓣狭窄的有效手段。随着 TAVR 在风险较低的患者中应用越来越广泛,器械故障的处理将变得越来越重要。
从 2011 年至 2015 年,STS 成人心脏外科学数据库中检索了既往接受 TAVR 并接受外科主动脉瓣置换术的患者的病史。为便于比较,采用观察到的与预期的(O/E)死亡率比值来评估再次手术的适应证和 TAVR 手术时间。
共纳入 123 例符合条件的患者(中位年龄为 77 岁),STS 预测死亡率为 4%、4%至 8%和>8%的患者分别占 17%、24%和 59%。中位再次手术时间为 2.5 个月(四分位间距:0.7 至 13.0),手术死亡率为 17.1%。再次手术的常见适应证包括早期 TAVR 器械故障,如瓣周漏(15%)、结构性假体恶化(11%)、修复失败(11%)、大小或位置问题(11%)和人工瓣膜心内膜炎(10%)。所有术前风险类别均与 O/E 死亡率比值增加相关(预测死亡率<4%:O/E 5.5;4%至 8%:O/E 1.7;>8%:O/E 1.2)。
与最初接受 SAVR 的相似患者相比,TAVR 早期失败后再次接受 SAVR 虽然罕见,但结局差于预期。需要继续积累这一不断发展的技术经验,以降低早期 TAVR 失败的发生率,并进一步确定失败的 TAVR 假体的最佳治疗方法。